Market Overview

FDA Asks Doctors To Suspend Use Of GlaxoSmithKline (GSK) Rotavirus Vaccine

Share:
FDA Asks Doctors To Suspend Use Of GlaxoSmithKline GSK Rotavirus Vaccine

The U.S. Food and Drug Administration announced on Monday that the agency has asked doctors to stop giving the GlaxoSmithKline PLC (NYSE: GSK) Rotarix vaccine on a temporary basis because extraneous viral components have been found in the vaccine.

The GlaxoSmithKline PLC Rotarix vaccine is given to infants to protect them from rotavirus.

The FDA said that porcine circovirus 1, or PCV1, is the suspected extraneous virus component.

PCV1 has not been known to make humans sick but the FDA is asking that use of the GlaxoSmithKline PLC Rotarix vaccine be suspended while it is studied.

The FDA also said that no PCV1 components had been found in the Merck & Company (NYSE: MRK) rotavirus vaccine RotaTeq.

 

Related Articles (GSK + MRK)

View Comments and Join the Discussion!

Posted-In: GlaxoSmithKline PLC Merck & Company Rotarix RotaTeq rotavirusNews FDA Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com